कंपनी का अवलोकन
Biomerica, Inc. is a biomedical technology enterprise dedicated to the development, patenting, manufacturing, and marketing of diagnostic and therapeutic products designed for the detection and treatment of various medical conditions and diseases on a global scale. The company operates within the Healthcare sector, specifically functioning in the Medical Devices industry, which implies a focus on tangible tools and systems used by healthcare professionals to deliver patient care. Biomerica, Inc. holds a market capitalization of $6.64M, generated $4.46M in annual revenue over the trailing twelve months, and employs a workforce of 53 individuals. These valuation and revenue figures indicate that the company operates on a small-cap scale, suggesting it is an early-stage or niche player with limited market penetration compared to larger pharmaceutical or device conglomerates. The relatively modest revenue base combined with a small employee count highlights a lean operational structure typical of specialized technology firms that may be in a growth or restructuring phase rather than a mature profit-generation phase.
वित्तीय स्वास्थ्य
The company reported a revenue of $4.46M for the trailing twelve months, yet it incurred a net loss of $-4,025,000, resulting in an EBITDA of $-5,179,000. The substantial gap between the $4.46M revenue and the negative net income reveals a highly inefficient cost structure where operating expenses significantly exceed gross profits, a common characteristic in capital-intensive research and development environments. Biomerica, Inc. generated negative free cash flow of $-1,701,375, which indicates that the company is consuming more cash than it produces from operations, thereby limiting its immediate financial flexibility to fund new projects without external financing. The gross margin stands at 5.6%, reflecting the low profitability of the core product sales before accounting for overhead costs. The operating margin is reported at -113.5%, and the profit margin is -90.3%, both of which signify that the company is burning cash at an aggressive rate, with operating costs far outweighing the revenue generated from product sales. Regarding liquidity and leverage, the company holds $2.54M in cash against $284,000 in debt, while maintaining a debt-to-equity ratio of 6.40. Although the current ratio of 3.25 suggests strong short-term liquidity and the ability to meet immediate obligations, the high debt-to-equity ratio indicates a leveraged balance sheet that relies heavily on equity financing or cash reserves to service obligations. The return on equity is -84.3% and the return on assets is -49.4%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently to generate positive returns.
मूल्यांकन आकलन
Biomerica, Inc. does not have a trailing P/E ratio as earnings are negative, but it displays a forward P/E of 5.64, which implies market expectations for future earnings growth that are currently absent given the recent financial history. The price-to-book ratio is 1.46, indicating that the market values the company at a premium of 46% above its tangible book value, potentially reflecting optimism regarding its intellectual property or future product pipeline. The price-to-sales ratio is 1.49, and the EV/EBITDA stands at -0.85; these alternative valuation metrics suggest that the company is priced based on revenue multiples rather than profitability, a standard practice for firms in loss-making phases of their lifecycle. The stock's 52-week trading range spans from a low of $1.87 to a high of $4.88, providing a historical context for price volatility within the current fiscal year. The beta value of 0.20 indicates that the stock's price volatility is significantly lower than the broader market, suggesting it behaves as a defensive or low-correlation asset during market fluctuations.
Growth & Income
The company experienced a revenue growth of -26.0% year-over-year, while earnings growth is listed as N/A due to the negative earnings position; this contraction implies that the business is facing significant headwinds or strategic shifts that are reducing its top-line sales velocity. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning it does not distribute cash to shareholders and instead retains any available cash for internal use or debt reduction. The absence of dividend payments aligns with the company's reinvestment strategy, where any retained earnings are directed toward research, development, or operational scaling rather than income distribution to investors. The overall growth and income profile is characterized by negative revenue expansion and a complete lack of current income generation, positioning the stock as a speculative play on future market capture rather than a current income vehicle.